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ABSTRACT 
The purpose of this study was to formulate and evaluate Parenteral Intraarticular Sustained-Release Formulation of an analgesic drug 
using the technology of in situ forming gel, based on temperature change mechanism in order to reduce the frequency of dosing and 
increase patient compliance in the treatment of knee pain. The formulation was optimized, prepared, filled aseptically, sterilized and 
evaluated for prerequisites of parenteral and other parameters like gelation temperature, gel strength, viscosity, drug content, in vitro 
and in vivo studies and stability studies. It was prepared using cold method and optimized by 32 factorial design, comprising of drug, 
Pluronic F127, HPMC K 100M and HPMC K4M was found to be clear, colorless, isotonic, sterile, pH as 6.8-7, viscosity of 1800 
cps, syringeable through 18 gauze needle, forming a stable in-situ gel at knee joint temperature having gel strength of 43.80 gm/cm 
showing a drug release of 95.88 % in phosphate buffer pH 7.4 at 120hrs. The sterile formulation packed in transparent ampoule was 
found to the stable with most suitable storage condition at the refrigerator temperature. Thus a biocompatible, stable parenteral 
formulation was developed which can be an alternative and convenient approach to the patients that require frequent parenteral 
administration, reducing the frequency of dosing and ultimately increasing patient compliance and comfort. 
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INTRODUCTION  
Analgesics are common medications used for moderate 
and severe pain given by a variety of different routes of 
administration which are effective for both nociceptive 
and neuropathic pain symptoms. Tramadol is a widely 
used analgesic that acts as a µ-opioid receptor agonist, 
altering the perception and response to pain, centrally 
and peripherally which are used in moderate to severe 
pain, available as immediate-release/orally disintegrating 
tablets (400 mg/day), extended-release tablets (300 
mg/day). It is widely used in case of knee pain either as 
in oral dosage forms or in injections forms (100mg/ 
day).
1 
One of the treatments for knee pain involves the 
intraarticular injections which are an attractive treatment 
for knee pain. An intraarticular route has been 
underestimated in the past years in the treatment of joint-
related disorders, and reliance on the systemic routes of 
administration prevailed instead. It involves the injection 
of medications like non-steroidal anti-inflammatory 
drugs (NSAIDS), hyaluronic acid and corticosteroids 
into a joint space, usually to reduce inflammation, pain 
and increasing function. These conventional treatments 
suffer from the drawbacks of fast drug leakage in joint 
cavity, provide only short-term pain relief, quick release 
and frequent dosing or multiple injections are needed. 
These drawbacks can be overcome with sustained drug 
delivery systems. Development of new sustained release 
injectable formulation has received considerable 
attention due to many advantages of these systems such 
as localized and site-specific action, prolonged delivery 
period, decreased drug dosages, reduction of side effects 
and improved patient comfort and compliance over the 
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conventional parenteral delivery. Such reduction in the 
frequency of drug dosing is achieved, in practice, by the 
use of specific formulation technologies that guarantee 
that the release of the active drug substance happens in a 
slow and predictable manner. In situ gel forming 
technology is one of the widely used systems that are 
fluids at room temperature and solidify when introduced 
into the body in a minimally invasive manner due to 
stimuli like pH change or temperature modulation. 
Advantages of this technology are the less complicated 
fabrication, a deliverance of accurate dose, ease of 
administration, reduced frequency of administration, 
improved patient compliance and comfort. One of the 
widely used polymer to achieve this is poloxamer 407 a 
thermosensitive polymer having the unique 
characteristic of phase transition i.e. sol-gel at body 
temperature 
2, 3, 4 
 Currently sustained release intraarticular injections are 
available in the market that gives the reduction in pain 
but has drawbacks like effects in the injected knee such 
as infection (with pain, swelling, and restricted motion) 
or joint damage, weakening of bones, inflammation at 
injection site.
5, 6
 
Thus our overall objective was to research and formulate 
Sustained release intraarticular injection of analgesic 
drug tramadol HCl using in-situ gel forming technology 
based on thermosensitive polymer, aiming to achieve a 
prolonged release of the drug over a period of 5 days. 
This would have the advantage of administration of a 
drug to the target site (IA) to overcome the drawbacks of 
conventional and achieve the advantage of 
administrating the dosage once a week and reducing the 
frequency of injections. 
MATERIALS AND METHOD 
Materials  
Tramadol HCL was obtained as a gift sample from 
Emcure Pharmaceuticals Pune.   PluronicF127 was 
provided by Ana lab fine chemical, Mumbai.Hydroxy 
propyl methyl celluloseK100M, K4M (HPMCK 100M, 
HPMC K4M) was provided by Chemica-biochemic-
reagents,Otto chemie,Pvt.Ltd. 
 Method 
1. Optimization study -  
A response surface statistical experimental design was 
used to optimize the effect of different independent 
factors on response. The responses were investigated 
using a Box–Behnken statistical experimental design 
using Design-expert software
®
 11 (Stat-Ease, Inc., USA) 
This design was based on a 3
2
factorial design, three 
replicates of the central run, leading to 9 sets of 
experiments, enabling each experimental response to be 
optimized. Different batches were prepared with 
different independent variables at different levels and 
responses. The criterion for selection of optimum 
formulations was based on the gelation at body 
temperature and highest gel strength to remain stable for 
prolonged period of time i.e. for 5 days. 
 
Table 1: Formulation combination as per the 3
2
 full factorial designs 
Formulation code HPMC K100M % (W/V) HPMC K4M % (W/V) 
F1 2 1.5 
F2 2 1 
F3 2 0.5 
F4 1.5 1.5 
F5 1.5 1 
F6 1.5 0.5 
F7 1 1.5 
F8 1 1 
F9 1 0.5 
 
The quality of the fitted model was expressed by the 
coefficient of determination R
2
, and its statistical 
significance was checked by an F-test (analysis of 
variance) at the 5% significance level. The statistical 
significance of the regression coefficients was 
determined by using the t-test (only significant 
coefficients with p-value < 0.05 are included). The 
optimum processing conditions were obtained by using 
graphical and numerical analysis based on the criteria of 
the desirability function and the response surface.
7 
2. Preparation of Formulation 
The formulation was prepared by using cold method. 
Drug was dissolved in water followed by addition of 
thermosensitive polymer Pluronic F127, stirred and kept 
in refrigerator at 4
°
c for 24 hrs to dissolve completely 
and form a clear solution. The other excipients like 
copolymer HPMC K100M,  HPMC K4M and tonicity 
adjusting agent NaCl were added to this solution and 
stirred continuously to dissolve to give complete clear 
viscous solution which was filled aseptically in 
transparent glass ampoules 2ml and sterilized by 
autoclaving at 121
°
C at 15 psi for 20 min and stored at 
refrigerator condition.
8, 9, 10, 11 
 Evaluation of Formulation 
1. Appearance & pH  
The optimized formulation was visually checked for its 
appearance and pH. The pH of the sol form was 
measured using standardized digital pH meter (Deluxe 
pH meter 101/EI) at room temperature by taking ade-
quate volume in a 10 ml beaker.
12 
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2. Gelation Temperature   
Gelation temperature was determined by modification of 
Miller and Doravan technique.   A 2 ml aliquot of gel 
was transferred to test tubes immersed in a cryostatic 
water bath at 20
° 
C and sealed with aluminum foil. The 
temperature of water circulation bath was increased with 
increments of 1
°
C and left to equilibrate for 5 min. at 
each new setting. The samples were examined for 
gelation which was said to have occurred when the 
meniscus would no longer move upon tilting through 90
° 
angle.
 8,9,10
 
3. Gel strength 
Gel strength was determined by Surimi test using 
Texture Analyzer (Texture Pro CT V1.4). Formulation 
(20 ml) was placed in 25 ml beaker and gelled using 
heating plate at 32˚C. The probe (TA 3/100) was 
allowed to traverse the gel up to 1 cm at a speed of 
1mm/s. The load reading was taken in g/cm for gel 
strength.
13 
4. Viscosity 
Viscosity was measured on Brookfield viscometer using 
RV (spindle no. 21) and T-type helipath spindle (spindle 
no. S21). Rheological behaviour was analyzed by 
subjecting the sample at temperature ambient 
temperature and 32˚C and variable shear stress.14 
5. Osmolality 
The samples were subjected to osmolality test using an 
Osmometer (Model 3250, Version 2.4).
 12
 
6. Syringiablity 
Syringiablity of the formulations was assured using 18 
to 22 gauge needles. Formulation was withdrawn into 
identical 5 ml plastic syringes placed with needles to a 
constant volume (1 ml). The solutions which were easily 
passed from a particular syringe were termed as pass 
and the ones which were difficult to pass were termed as 
fail.
12
 
7. Drug content estimation  
The quantity of formulation equivalent to 10mg of 
Tramadol HCL was taken and diluted with 10ml of 
methanol (1000 μg/ml) and was diluted up to 10 ml with 
methanol to get a stock solution of (100μg/ml). From 
this stock solution, a solution of 50 μg/ml was prepared 
and analyzed by UV spectrophotometer and HPLC. The 
concentration of the drug present in the formulation was 
computed from the calibration curve using the equation 
y = mx+ c.
15 
8. Sterility Testing 
Sterility testing was carried out as per the IP 2014. The 
formulation was incubated for not   less than 14 days at 
30-35
°
C in the alternate fluid thioglycolate medium to 
find the growth of bacteria & at 20
°
C-25
°
C in Soya bean 
casein digest medium to find the growth of fungi in 
formulation. The test was performed using positive and 
negative controls.
16, 17
 
9. In-vitro Drug Release Studies 
The in vitro drug release studies of Tramadol HCL in-
situ gel forming sustained release injectable were carried 
out using Orbital Shaking Incubator (REMI model) to 
maintain the temperature at 32˚C and agitated at 30 rpm 
for 5 days. This speed was kept slow enough to avoid 
the breaking of gelled formulation under mild agitation 
conditions similar to physiological conditions. The 
dissolution medium used was phosphate buffer (pH 7.4).  
1 ml of aliquots was withdrawn at specific time intervals 
(1, 24, 48, 72, 96, 120 hrs) and replenished with fresh 
medium to maintain the sink conditions. Aliquots 
withdrawn were filtered, suitably diluted and analyzed 
using UV spectrophotometer (V-530, Jasco) at 271nm. 
Percentage cumulative drug release (% CDR) was 
calculated using an equation obtained from a calibration 
curve.
18, 19 
9. Determination of drug release kinetics 
To describe the kinetics of the drug release from the 
sustained release in-situ gel, mathematical models such 
as Zero-order, First-order, Higuchi, Hixon-Crowell, 
Korsmeyer-peppas models were evaluated by model-
dependent (curve fitting) method using PCP Disso 
V2.08 software.
20, 21
 
10. Accelerated Stability study  
 Stability studies were carried out on optimized 
formulation according to International Conference on 
Harmonization (ICH) guidelines. A sufficient quantity 
of formulations were kept at room temperature i.e. at 
25
°
C ± 2
°
C/60% ± 5% RH, refrigerator i.e. at 5
°
C± 3
°
C 
and accelerated conditions(40
°
C±5
°
C/75±5%RH) for 1 
month. After 1 month samples were evaluated for 
appearance, pH, clarity, gelation temperature, % drug 
content and in vitro drug release.
22, 23 
RESULTS AND DISCUSSIONS 
Optimization study  
The design of experiment (DOE) is an approach in 
which process variables are first screened and then 
optimized to determine best settings for the variables. 
The full factorial design is a quadratic design which 
requires 3 levels (-1, 0, +1) for each factor. In which the 
concentration of HPMC K100M and HPMC K 4M were 
selected as the independent variables whereas Gel 
strength and Drug release were selected as the 
dependent variables. The interactions between the 
factors were demonstrated using 3-D graphs. The 
experimental values obtained were compared with those 
predicted by the mathematical models. The data 
generated is given in Table 3 which was analyzed using 
Design Expert software version 11.0 and polynomial 
equations were obtained for the same. 
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Table 2: 3
2
 experimental design with response 
Formulation 
code 
Gel strength 
(gm/cm) 
% Drug release 
(At 96 hrs) 
% Drug release (At 
120 hrs) 
F1 46.50 50.61 62.18 
F2 42.80 61.04 73.06 
F3 41.00 93.93 - 
F4 44.10 55.70 78.90 
F5 43.80 84.65 97.05 
F6 42.95 95.56 - 
F7 41.70 54.94 68.65 
F8 42.30 100 - 
F9 41.40 100 - 
 
Response Surface plots: 
(1) Gel strength  
 
Figure 1: Response surface of gel strength 
 
Above response surface plot showed that as the 
concentration of HPMCK100M increases, the gel 
strength increases. Similarly for other polymer to 
withstand the various body shear forces, gel must have 
the sufficient gel strength which was imparted by the 
addition of HPMC K100M and HPMC K4M. 
In the equation, A & B having positive effect on gel 
strength. The interaction terms A & B have synergistic 
effect on gel strength. 
Analysis of variance has been calculated to analyze the 
accessibility of the model. The F distribution is a 
probability distribution used to compare variances by 
examining their ratio. If they are equal then F value 
would equal to one. The F value in the ANOVA table is 
the ratio of model mean square (MS) to the appropriate 
error mean square. The larger the ratio, the larger the F 
value and the more likely that the variance contributed 
by the model is significantly larger than random error. 
As a general rule, if p-value is less than 0.05, model 
parameter is significant. 
On the basis of analysis of variance, the conclusion is 
that the selected model adequately represents the data 
for the formulation of prolonged release parenteral drug 
delivery system. Final Equation of gel strength in terms 
of Coded Factors 
Gel strength= + 36.82+6.166*A+0.983*B + 0.800*A*B 
+ 1.333*A
2 
+ 0.5666*B
2
.... (1) 
Where, A is concentration of HPMC K100M and B is 
the concentration of HPMC K4M. 
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(2) Drug Release: 
 
Figure 2: Response surface for Drug Release 
Figure 2 shows the combined effect of HPMC K 100M 
and HPMC K4M on drug release. In order to obtain a 
sustained release over a 5 day period, it was necessary 
for the in situ gel formed to have a sufficient strength 
and stability. Alone HPMC K100M could not impart 
these parameters so HPMC K 4M was added as a 
copolymer to reduce the burst release. It is observed 
from the plot that concentration HPMC K 100 M has 
pronounced effect on drug release because as the 
concentration of HPMC K100M increases, drug release 
gets sustain. 3D response surface plot for drug release 
showed that decreasing the concentration of HPMC K 
100M at a higher level of HPMC K4M resulted in a 
lower degree of drug release. 
Final Equation of Drug release in terms of Coded 
Factors: 
Drug release = +220-86.43*A-
56.10*B+5.300*A*B+12.84*A
2
+11.62*B
2… (2) 
Where, A is concentration of HPMC K100M and B is 
the concentration of HPMC K4M. In this case, A and B 
were found to be significant model terms. The positive 
coefficient of B indicated that as the concentration of 
HPMC K 4 M increased, the drug release also gets 
decreased.  The negative sign of A is indicating that 
lower the concentration of HPMC K 100M, the higher 
will be the drug release. The low coefficient of A 
indicated that HPMC K 100M concentration affected 
drug release to a greater extent than HPMC K 4 M 
concentration. The positive coefficient for term AB for 
the combined effect of both factors was found to have a 
positive effect.  
In order to find out the contribution of each component 
and their interaction, Analysis of Variance (ANOVA) 
was carried. The ANOVA analysis of the quadratic 
model showed that the model was significant (p<0.05) 
which was also supported by the high F value and with 
the adequate Precision (ratio>4) was observed as shown 
in Table 3 and validation of the Response Surface 
Methodology are shown in Table 5. 
 
Table 3: ANOVA studies 
Response 
variables 
F value  P value Adj R2  Pred R2  Adequate 
Precision 
Gel strength 132.46 0.0018 0.9578 0.9367 31.26 
% Drug Release 38.95 0.0051 0.97.64 0.8854 18.957 
 
Table 4: Desirability function of optimized formulation 
Formulation code  HPMC K100M 
(%W/V) 
HPMC K4M 
(%W/V) 
Desirability 
F5 1.5 1 0.966 
Design-Expert® Software
Trial Version
Factor Coding: Actual
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Table 5: Validation of the Response Surface Methodology (RSM) 
Responses Experimental value Predicted value % Predicted error 
Gel strength  43.80 44.50 0.7 
% drug release  95.88 97.89 2.01 
 
Appearance and pH 
All the formulations were clear and colourless. Terminal 
sterilization with autoclaving had no effect on physical 
and chemical properties of the formulation. The pH of 
the all the formulations was found to be between 6.8 -7. 
Moreover, the drug was found to be most stable in this 
pH range. Thus the formulation follows all the 
prerequisites of the parenteral dosage form. 
 Gelation temperature 
The gelation temperature of the optimized formulation 
was found to be 32°C. This temperature was sufficient to 
trigger in situ gel formation. 
Pluronic F127 (P407) is a triblock copolymer with a 
central hydrophobic chain of polyoxypropylene (PPO) 
and two identical lateral hydrophilic chains of 
polyoxyethylene (PEO). As the concentration of 
Pluronic increases i.e. above micelle concentration, there 
is formation of micelle structure followed by 
aggregation of micelle. In cold water, hydrogen bonding 
between POP chains and water keeps the hydrophobic 
portions of the Pluronic apart and increase in 
temperature leads to disruption of the hydrogen bonds 
and occurrence of hydrophobic interactions and 
formation of gel. Therefore, the gelling properties of the 
Pluronic are dependent on percentage of hydrophobic 
portion. As the concentration of Pluronic F127 increases, 
the hydrophobic portion also increases resulting in 
formation of gel at lower temperature.  
 
 
Figure 3: Effect of concentration of PF127 on gelation temp 
 
Gel strength 
Gel strength of optimized formulation was found to be 
43.80 gm/cm. Gel strength provides overview of the 
mechanical properties of gel. It also signifies the ability 
of gelled mass to withstand shear forces in the body for 
prolonged period of time. The Gel strength of 
formulation was important variable dependent on the 
concentration of gelling agent i.e. Pluronic F127. 
Pluronic F127 (25%) reveals that it does not have 
sufficient gel strength so HPMCK100M were added 
which increases the gel strength, by forming 
hydrophobic interaction between the Pluronic F127 and 
HPMC K100M molecules. 
Viscosity 
The viscosity of optimized formulation was found to be 
1800 cP. To administer the gel easily into the body it 
should possess optimal viscosity. Further the 
formulation undergoes sol to gel transition upon contact 
with body temperature. Pluronic F127 does not have 
sufficient viscosity to remain its integrity in body for 
prolonged period of time so HPMC K100M was added 
which impart viscosity in the formulation.  
Osmolality 
The Osmolality of the sample was found to be 
313mOsmol/L 
Syringeability – 
The optimized formulation was easily passed through 
the needle gauge 18. This needle size was suitable for 
intraarticular injection.  
Drug content 
The percentage drug content in the formulation was 
calculated and found to be 97.85%, indicating 
insignificant loss of drug during the formulation. 
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Sterility testing 
Test for bacteria & fungi 
                              Table 6: Observations for bacterial & fungal growth 
 
 
 
 
 
No turbidity was observed after 14 days. It passes the 
sterility test. The formulation was found to be free from 
bacteria and fungi and hence suitable for parenteral and 
administration. Thus the sterility of the formulation may 
be attributed to aseptic process of preparation and filling 
the container and autoclaving at 121°C at 15 psi for 20 
min. 
In vitro Release study 
In vitro drug release study serves as an important tool in 
formulation and development. Drug release from 
Pluronic F127 gel into release medium was regulated by 
dissolution or diffusion of drug, depending upon 
experimental conditions. In vitro drug release of gel 
formulation was regulated by diffusion mechanism. 
Pluronic F 127 immediately converts into gel form at 
body temperature and when the formulation got exposed 
to the preheated phosphate buffer pH 7.4 at 32
0
C it 
undergoes phase transition from sol-gel and forms a 
barrier for a drug release. As the time passes the outer 
layer become more hydrated and the polymer chains 
become fully relaxed and leading to erosion from the 
surface. As the concentration of HPMC K100M, HPMC 
K4 M increases drug release was retarded. Thus drug 
release was regulated by diffusion and erosion 
mechanism. Studies were performed in a triplicate 
which shows about 95.88 % release after completion of 
5 days. 
 
Figure: 4 In-vitro drug release 
Kinetics and mechanism of drug release 
Kinetic results shown in Table reveals that the best fit 
model for optimized batch was zeroorder kinetics as 
correlation coefficient (r2) values are higher than other 
release kinetics. The calculated n values from power law 
equation for drug release profiles were between 0.5119- 
0.7523 with a correlation coefficient (r2) values > 0.93, 
suggest that the optimized formulation followed non-
Fickian (anomalous) diffusion mechanism for drug 
release.
 
Table 7: Model for release kinetics 
Formulation F5 Zero order First order Korsemeyer- Peppas order 
 
Higuchi order 
 
R2 0.983 0.932 0.912 0.884 
 
Accelerated Stability testing 
Stability studies indicate that optimized formulation was 
physically and chemically stable at ambient temperature 
i.e. at 25°C ± 2°C/60% RH ± 5% RH  and at accelerated 
conditions 40°C ± 2°C/75% RH ± 5% RH and at 
refrigerator conditions i.e. at 5°C ± 3°C for a period of 1 
month. From stability studies, it was observed that the 
formulation of Tramadol HCL was stable at selected 
storage conditions with most suitable storage condition 
at the refrigerator temperature. It showed that there was 
no change in colour, gelation temperature but slightly 
decrease in pH, gel strength and in vitro drug release 
profile at 40°C. 
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Mirajkar et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2018; 8(4):209-217           
ISSN: 2250-1177                                                                             [216]                                                                             CODEN (USA): JDDTAO 
Table 8: Stability studies results after 1 month 
Evaluation 
parameters 
Initial After storage at room 
temperature 
After storage at 
40±2
o
C/75±5% 
After storage at 
refrigerator temp 
Appearance  clear, colorless clear, colorless clear, colorless clear, colorless 
pH 7.3 7.1 6.8 7.2 
Gelation temperature 32° C 32° C 32° C 32° C 
Gel strength (gm/cm) 43.80 48.60 47.50 43.30 
Drug content 97.85 95.51 94.65 96.24 
Syringeability Passes Passes Passes Passes 
In vitro drug release at 120 
hrs after 1 month 
95.88           93.75 90.52 94.56 
 
  
Figure: 5 In-vitro drug release after 1 month 
 
CONCLUSION  
Thus formulation of tramadol hydrochloride as an 
intraarticular in situ gelling parenteral drug delivery 
system is an alternative to the conventional and 
sustained release formulations owing to its ability to 
achieve a prolonged release of the drug over a period of 
5 days with administration of a drug to the target site 
(IA) which overcome the drawbacks of conventional and 
gives the advantage of administrating the dosage once a 
week and reduced the frequency of injections and 
improves patient compliance. The formulation involves 
less complicated fabrication and easy administration. 
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